non-hodgkin's%20lymphoma
NON-HODGKIN'S LYMPHOMA

Non-Hodgkin's lymphoma is a heterogeneous group of lymphoproliferative malignancies.
It is the most common hematologic cancer.
The most common subtypes are the diffuse large B-cell and follicular lymphoma. The subtypes are based on the malignant cell's morphology, genetic features, immunohistological characteristics, and stage of maturation.

Radiotherapy

Indolent Stage I/Contiguous Stage II NHL
  • Studies suggest doses of 25-40 Gy
  • May be given as local or extended-field RT
Aggressive Stage I/Contiguous Stage II NHL
  • Involved site radiation therapy (ISRT) may be given with or without chemotherapy (usually R-CHOP)
    • Studies have shown an increase in the overall survival & event-free survival rates of patients given CHOP with involved-site radiation therapy (ISRT)
Indolent Noncontiguous Stage II/III/IV NHL
  • Studies suggest doses of 25-40 Gy
  • Total body irradiation (TBI), EF-XRT, & TBI followed by high-dose radioimmunotherapy are still under clinical evaluation & needs further studies to prove efficacy in patients with indolent noncontiguous stage II/III/IV NHL
Aggressive Noncontiguous Stage II/III/IV NHL
  • Local-field XRT is recommended with combination chemotherapy
Recurrent NHL
  • Low dose involved site radiation therapy (ISRT) is recommended to indolent/aggressive relapsed NHL patients for palliative purposes
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Christina Lau, 13 Feb 2018

Combining gabapentin or pregabalin with opioid analgesics does not significantly improve cancer pain relief compared with opioid monotherapy, according to results of a recent systematic review and meta-analysis.

22 Jan 2018
In a symposium chaired by Dr Yoon-Sim Yap of the National Cancer Centre Singapore, renowned regional and international experts in the field of breast cancer, Dr Yen-Shen Lu from Taiwan and Professor Nadia Harbeck from Germany, joined her in providing insights on the current treatment landscape of hormone receptor-positive (HR+) advanced breast cancer. In their respective sessions, they each highlighted new therapeutic options including the optimal use of dual blockade therapy for oestrogenreceptor-positive (ER+) advanced breast cancer for patients in Asia.